The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes.

På svenska

Author

Summary, in English

Type 2 diabetes (T2D) is a progressive disorder with a consistent and steady increase in glycosylated hemoglobin (HbA1c) over time associated with enhanced risk of micro- and macrovascular complications and a substantial reduction in life expectancy. There are three major pathophysiologic abnormalities associated with T2D: impaired insulin secretion, excessive hepatic glucose output, and insulin resistance in skeletal muscle, liver, and adipose tissue. These defects have been treated in clinical praxis by use of oral insulin secretagogues (sulfonylureas/ glinides) or insulin, biguanides, and thiazolidinediones (TZDs) respectively. Pioglitazone HCL is an insulin sensitizer in the TZD family and glimepiride is an insulin secretagogue in the SU family. This article reviews mechanisms of action and clinical data behind the use of these two commonly used oral hypoglycemic agents with documented efficacy and good safety profile of once-daily administration, alone or in combination with insulin or metformin, in the management of T2D in terms of glycemic and non-glycemic effects, tolerability and side effects, and impact on vascular health.

Publishing year

2007

Language

English

Pages

721-731

Publication/Series

Vascular Health and Risk Management

Volume

3

Issue

5

Document type

Journal article review

Publisher

Dove Medical Press Ltd.

Topic

  • Cardiac and Cardiovascular Systems

Keywords

  • Sulfonylurea Compounds: therapeutic use
  • Thiazolidinediones: therapeutic use
  • Diabetes Mellitus
  • Sulfonylurea Compounds: adverse effects
  • Type 2: drug therapy
  • Type 2: blood
  • Blood Glucose: metabolism
  • Thiazolidinediones: adverse effects

Status

Published

Research group

  • Genomics, Diabetes and Endocrinology

ISBN/ISSN/Other

  • ISSN: 1178-2048